Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5 Pt 1
|
| pubmed:dateCreated |
1995-6-19
|
| pubmed:abstractText |
To evaluate the long-term protection afforded by the vaccine, recombinant hepatitis B (HB) vaccine was given to 171 infants born to hepatitis B e antigen-positive carrier mothers. Group A (53 infants) and group B (57 infants) received four doses of HB vaccine at birth and at 1, 2, and 12 months of age, with a dose of 20 micrograms in group A and 10 micrograms in group B. Group C (61 infants) received three 20 micrograms doses of HB vaccine at birth and at 1 and 6 months of age. These children were followed up annually up to 5 years of age. Six children (4%) became HB carriers before 1 year of age, and the carrier state persisted to the end of follow-up. The overall seropositive rate of HB surface antibody (anti-HBs) dropped from 99% at 1 year of age to 83% at 5 years of age. Among 548 serum pairs taken at 1-year intervals from children negative for HB surface antigen (HBsAg), a fourfold rise of anti-HBs titer was noted in 58 (11%) and a 10-fold rise of anti-HBs was noted in 17 (3%). Maternal HB core antibody disappeared in most children (151/152, 99%) before 2 years of age. Natural infections, as judged by persistence or reappearance of HB core antibody, occurred in 19 of 163 (12%) HBsAg-negative children. None of these episodes was associated with HBsAg positivity. We conclude that the long-term protection afforded by recombinant HB vaccine is satisfactory and that a further booster dose before 5 years of age is not necessary.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Engerix-B,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Surface Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B e Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0022-3476
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
126
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
716-21
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:7751994-Biological Markers,
pubmed-meshheading:7751994-Carrier State,
pubmed-meshheading:7751994-Child, Preschool,
pubmed-meshheading:7751994-Female,
pubmed-meshheading:7751994-Follow-Up Studies,
pubmed-meshheading:7751994-Hepatitis B,
pubmed-meshheading:7751994-Hepatitis B Antibodies,
pubmed-meshheading:7751994-Hepatitis B Surface Antigens,
pubmed-meshheading:7751994-Hepatitis B Vaccines,
pubmed-meshheading:7751994-Hepatitis B e Antigens,
pubmed-meshheading:7751994-Humans,
pubmed-meshheading:7751994-Immunity, Innate,
pubmed-meshheading:7751994-Immunization, Secondary,
pubmed-meshheading:7751994-Immunization Schedule,
pubmed-meshheading:7751994-Infant,
pubmed-meshheading:7751994-Infant, Newborn,
pubmed-meshheading:7751994-Infectious Disease Transmission, Vertical,
pubmed-meshheading:7751994-Mothers,
pubmed-meshheading:7751994-Regression Analysis,
pubmed-meshheading:7751994-Risk Factors,
pubmed-meshheading:7751994-Time Factors,
pubmed-meshheading:7751994-Vaccines, Synthetic
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen.
|
| pubmed:affiliation |
Department of Pediatrics, National Taiwan University Hospital, Taipei, Republic of China.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|